Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,708

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Drug—target network

Yıldırım, Muhammed A, Goh, Kwang-Il, Cusick, Michael E, Barabási, Albert-László, Vidal, Marc·2007·Nature Biotechnology
DOI 10.1038/nbt1338
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nbt1338

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 28

  1. Imming, P., Sinning, C. & Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821–834 (2006). · DOI · Paper page
  2. Russ, A.P. & Lampel, S. The druggable genome: an update. Drug Discov. Today 10, 1607–1610 (2005). · DOI · Paper page
  3. Drews, J. Stategic trends in the drug industry. Drug Discov. Today 8, 411–420 (2003). · DOI · Paper page
  4. Han, J.-D. et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 430, 88–93 (2004). · DOI · Paper page
  5. Jeong, H., Mason, S., Barabasi, A.-L. & Oltvai, Z. Lethality and centrality in protein networks. Nature 411, 41–42 (2001). · DOI · Paper page
  6. Vidal, M. Interactome modeling. FEBS Lett. 579, 1834–1838 (2005). · DOI
  7. Goh, K.I. et al. The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685–8690 (2007). · DOI · Paper page
  8. Jimenez-Sanchez, G., Childs, B. & Valle, D. Human disease genes. Nature 409, 853–855 (2001). · DOI · Paper page
  9. Peltonen, L. & McKusick, V. Dissecting human disease in the postgenomic era. Science 291, 1224–1229 (2001). · DOI · Paper page
  10. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805–815 (2006). · DOI · Paper page
  11. Mencher, S.K. & Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5, 3 (2005). · DOI · Paper page
  12. Newman, M.E. Scientific collaboration networks. I. Network construction and fundamental results. Phys. Rev. E 64, 016131 (2001). · DOI · Paper page
  13. Cokol, M., Iossifov, I., Weinreb, C. & Rzhetsky, A. Emergent behavior of growing knowledge about molecular interactions. Nat. Biotechnol. 23, 1243–1247 (2005). · DOI
  14. Rual, J.-F. et al. Toward a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173–1178 (2005). · DOI · Paper page
  15. Stelzl, U. et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122, 957–968 (2005). · DOI · Paper page
  16. Eppig, J.T. et al. The Mouse Genome Database (MGD): from genes to mice–a community resource for mouse biology. Nucleic Acids Res. 33, D471–D475 (2005). · DOI · Paper page
  17. Ge, X. et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86, 127–141 (2005). · DOI
  18. Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A. & McKusick, V.A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514–D517 (2005). · DOI · Paper page
  19. Butcher, E.C., Berg, E. & Kunkel, E. Systems biology in drug discovery. Nat. Biotechnol. 22, 1253–1259 (2004). · DOI · Paper page
  20. Chanda, S.K. & Caldwell, J. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8, 168–174 (2003). · DOI
  21. Searls, D.B. Pharmacophylogenomics: genes, evolution and drug targets. Nat. Rev. Drug Discov. 2, 613–623 (2003). · DOI
  22. van der Greef, J. & McBurney, R. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4, 961–967 (2005). · DOI · Paper page
  23. Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463–469 (2002). · doi:10.1038/nrd823
  24. Gershell, L.J. & Atkins, J. A brief history of novel drug discovery technologies. Nat. Rev. Drug Discov. 2, 321–327 (2003). · DOI
  25. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493–502 (2002). · DOI · Paper page
  26. Babu, M.M., Luscombe, N.M., Aravind, L., Gerstein, M. & Teichmann, S.A. Structure and evolution of transcriptional regulatory networks. Curr. Opin. Struct. Biol. 14, 283–291 (2004). · DOI · Paper page
  27. Rodriguez-Caso, C., Medina, M.A. & Sole, R.V. Topology, tinkering and evolution of the human transcription factor network. FEBS J. 272, 6423–6434 (2005). · DOI
  28. Wagner, A. & Fell, D.A. The small world inside large metabolic networks. Proc. Biol. Sci. 268, 1803–1810 (2001). · DOI · Paper page

Cited by

See all 1,708

Metadata

Authors
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M.
Venue
Nature Biotechnology
Publisher
Springer Science and Business Media LLC
Published
2007-10
Volume
25
Issue
10
Pages
1119-1126
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
DOI
10.1038/nbt1338
OpenAlex
W1544009106
Cited by
1,708
References
9
FWCI
83.35
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug—target network. https://app.cochat.ai/papers/10.1038/nbt1338
The paper
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug—target network. Nature Biotechnology. https://doi.org/10.1038/nbt1338

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.